What's New


License Agreement Has Been Entered with Thyas Co. Ltd.

We executed a worldwide license agreement with Thyas Co. Ltd. (Kyoto, Japan) for the use of iPS cell-derived T cells for autologous immunotherapy of cancers and infectious diseases, the license allowing exclusive rights on patents related to T cell induction and non-exclusive rights on the patents related to iPS cell technology and, for all of which sublicensing rights have been granted to us by Kyoto University.

Thyas Co. Ltd.

Back to top